Abstract
Purpose
Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) and lymphoblasts.
Methods
To clarify the pharmacokinetic interactions between these two antimetabolites, we serially measured RBC 6-TGN and MTX polyglutamates (MTXPG) levels following repeated courses of HDMTX (5 g/m² over 24 h) with daily oral 6-MP (25 mg/m²) during interval therapy in 20 children with ALL.
Results
HDMTX produced a rapid reduction in RBC 6-TGN 24 h after the start of MTX, and this effect was sustained at least by the third day (median decrease −21%; P < 0.001). However, a return to pre-infusion of 6-TGN levels was observed by the time of the following HDMTX course 14 days later (P < 0.001). RBC MTX polyglutamates accumulation followed Michaelis–Menten kinetics but was not associated with the change in pre-infusion 6-TGN levels which remained stable during the interval period.
Conclusion
HDMTX does not appear to enhance 6-MP activation to 6-TGN. Moreover, given that the deleterious effect of HDMTX on intracellular 6-MP disposition has been shown to be several folds greater in lymphoblasts than in RBC. Our data warrant additional studies elucidating the optimal MTX dose synergizing with 6-MP.
Similar content being viewed by others
References
Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730–2741
Frei E III, Freireich EJ, Gehan E, Pinkel D, Holland JF et al (1961) Studies of sequential and combination antimetabolite therapy in acute lymphoblastic leukemia: 6-mercaptopurine and methotrexate. Blood 18:431–453
Lennard L (1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43:329–339
Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041–1048
Bokkerink JP, Bakker MA, Hulscher TW, De Abreu RR, Schretlen ED, van Laarhoven JP, De Bruyn CH (1986) Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol 35:3549–3555
Tan CT, Wollner N, Trippett T, Goker E, Tong WP, Kheradpour A et al (1994) Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies. J Clin Oncol 12:1955–1962
Lewis AS, Murphy L, McCalla C, Fleary M, Purcell S (1984) Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin. J Biol Chem 259:12–15
Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, Gilchrist GS, Hammond D, Poplack DG (1987) The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 41:384–387
Dervieux T, Hancock M, Evans W, Pui CH, Relling MV (2002) Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 16:209–212
Dervieux T, Hancock ML, Pui C-H, Rivera GK, Sandlund JT, Ribeiro R, Boyett J, Evans WE, Relling MV (2003) Antagonism of methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther 73:506–516
Dervieux T, Boulieu R (1998) Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 44:551–555
Dervieux T, Orentas LD, Marcelletti J, Pischel K, Smith K, Walsh M, Richerson R (2003) HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 49:1632–1641
Schmiegelow K, Schroder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L (1995) Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic society for pediatric hematology and oncology. J Clin Oncol 13:345–351
Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high- dose methotrexate. J Clin Invest 97:73–80
Schroder H, Clausen N, Ostergaard E, Pressler T (1986) Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. Cancer Chemother Pharmacol 16:190–193
Hendel J, Nyfors A (1984) Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur J Clin Pharmacol 27:607–610
Dervieux T, Brenner TL, Hon YY, Zhou Y, Hancock ML, Sandlund JT et al (2002) De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 100:1240–1247
Schroder H, Fogh K, Schrder H (1988) Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 21:145–149
Allegra CJ, Drake JC, Jolivet J, Chabner BA (1985) Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 82:4881–4885
Rostami-Hodjegan A, Lennard L, Lilleyman JS (1995) The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol 40:217–222
Giverhaug T, Loennechen T, Aarbakke J (1998) Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate. Biochem Pharmacol 55:1641–1646
Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, Macchia P, Del Tacca M (1996) Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 37:409–414
Lennard L, Lilleman JS (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816–1823
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adam de Beaumais, T., Dervieux, T., Fakhoury, M. et al. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 66, 653–658 (2010). https://doi.org/10.1007/s00280-009-1205-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1205-4